RxDoctor Payments Data

William Figlesthaler, MD

Urology · Naples, FLNPI 1255379277

Payments from drug & device makers

$872in general payments, 2019–2025

Across 38 payments — averaging $22.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$210
  • Boston Scientific$146
  • Janssen Scientific Affairs, LLC$134
  • AbbVie$132
  • Laborie Medical Technologies Corp.$60
  • Ambu Inc.$46
  • plus $145 from 7 others

What the payments were for

  • Food & beverage$872100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$872 in reported general payments places this provider in the 20th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$1,154,404
Medicare patients
1,599
Services billed
20,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron30$25,194
MyrbetriqMirabegron11$13,836
Silodosin48$4,176
Tamsulosin Hcl146$1,953
Solifenacin Succinate41$1,813
Finasteride63$1,050
Estradiol18$964
Methenamine Hippurate16$802
Oxybutynin Chloride17$376
Bethanechol Chloride12$367
Bicalutamide11$351
Ciprofloxacin Hcl42$245
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen20$122
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim38$114
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$96

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$17$25,19430 claims
Astellas Pharma US IncMyrbetriq$210$13,83611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 935 urology providers in Florida.

Other urology in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →